Just a moment, the page is loading...
Welcome to the Janssen Oncology & Haematology IIS Website
Janssen Oncology
Selected Products:
Clear AllClose



Clinical Application Details


Drug:

Ibrutinib

Status:

Accepting Clinical IIS Applications 1 July - 30 August, 2019




New applications will be received 1 July - 30 August, 2019

Review decisions will be communicated in Q4 2019

Ibrutinib is being co-developed as a strategic partnership between Janssen Pharmaceuticals and Pharmacyclics. Both companies are responsible for the development, manufacturing, and commercialization of ibrutinib. Ibrutinib-related information submitted on this website will be shared between the two companies.

Click on "Submit Application" below to begin the process.

NOTE: If you are a researcher residing in the United States (US), please access the Pharmacyclics IIS portal via: http://www.bcellpartners.com US applications will not be accepted on this website.